NEW ZEALAND DATA SHEET

1. PRODUCT NAME

DuoTrav™ (travoprost 0.004% and timolol 0.5%) Eye Drops

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

DuoTrav Eye Drops contain a combination of travoprost 0.004% and timolol maleate 0.68% (equivalent to timolol 0.5%).

Excipient with known effect

Polyquaternium-1 (POLYQUAD™) as a preservative.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Eye drops, solution.

4. CLINICAL PARTICULARS

4.1. Therapeutic indications

Reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension for whom single agent therapy provides insufficient intraocular pressure reduction.

4.2. Dose and method of administration

Recommended dosage for adults (including the elderly)

Instil one drop of DuoTrav Eye Drops once daily at about the same time each day in the conjunctival sac of the affected eye(s).

DuoTrav Eye Drops should not be given more than once daily because travoprost is most effective at this dosage. If there is inadequate response to DuoTrav Eye Drops consideration should be given to using the individual agents with timolol dosed twice daily.

If more than one topical ophthalmic product is being used, the eye drop products should be administered at least five minutes apart.

Switching to therapy with DuoTrav Eye Drops

When substituting another ophthalmic antiglaucoma agent with DuoTrav Eye Drops, discontinue the other agent and start the following day with DuoTrav Eye Drops.

4.3. Contraindications

DuoTrav Eye Drops are contraindicated in patients with a known hypersensitivity to travoprost, timolol or any of the excipients listed under Section 6.1.

DuoTrav Eye Drops are also contraindicated in pregnant women or women attempting to become pregnant (See Section 4.6 Fertility, pregnancy and lactation, Pregnancy).

Reactive airway disease including bronchial asthma, a history of bronchial asthma, or severe chronic obstructive pulmonary disease.

Sinus bradycardia, sick sinus syndrome, including sino-atrial block, second or third degree atrioventricular block, overt cardiac failure or cardiogenic shock.

4.4. Special warnings and precautions for use

Not for injection or oral ingestion.
**Cardiovascular/respiratory reaction**

Like other topically applied ophthalmic agents, DuoTrav may be absorbed systemically. Due to the beta-adrenergic component timolol, the same types of adverse reactions seen with systemic beta-blockers may occur including aggravation of Prinzmetal angina, aggravation of severe peripheral and central circulatory disorders, bradycardia and hypotension.

In patients with cardiovascular diseases (e.g. coronary heart disease, Prinzmetal's angina and cardiac failure) and hypotension, therapy with beta-blockers should be critically assessed and therapy with other active substances should be considered. Patients with cardiovascular diseases should be monitored for signs of deterioration of these diseases and for adverse reactions.

Patients with severe peripheral circulatory disturbance/disorders (i.e. severe forms of Raynaud's disease or Raynaud's syndrome) should be treated with caution.

Respiratory and cardiac reactions, including death due to bronchospasm in patients with asthma and rarely death associated with cardiac failure have been reported following administration of timolol. Cardiac failure should be adequately controlled before treatment.

**Anaphylactic reactions**

While taking beta-blockers patients with a history of atopy or a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge with such allergens, whether accidental, diagnostic or therapeutic. In addition, such patients may be unresponsive to the usual doses of adrenaline used to treat anaphylactic reactions.

**Concomitant therapy**

Timolol may react with other drugs (see Section 4.5 Interactions with other medicinal products and other forms of interactions). The effect on IOP or the known effects of systemic beta-blockade may be exaggerated when DuoTrav Eye Drops is given to patients already receiving an oral beta-blocking agent. The response of these patients should be closely monitored. The use of two topical beta-blockers or topical prostaglandins is not recommended.

The use of DuoTrav Eye Drops may be considered in patients who require both timolol and travoprost, but it is unknown whether patients who are adequately controlled with timolol given twice daily plus travoprost given once daily will be as well controlled with DuoTrav Eye Drops given once daily. DuoTrav Eye Drops should not be used to initiate therapy.

**Additional effects of beta-blockade**

Beta-blockers should be administered with caution in patients subject to spontaneous hypoglycaemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycaemic agents. Beta-blockers may mask the signs and symptoms of acute hypoglycaemia.

Therapy with beta-blockers may mask certain symptoms of hyperthyroidism and abrupt withdrawal of therapy may precipitate a worsening of symptoms.

Therapy with beta-blockers may aggravate symptoms of myasthenia gravis.

**Surgical anaesthesia**

Beta-blocking ophthalmological preparations may block systemic beta-agonist effects.
e.g. of adrenaline. The anaesthesiologist should be informed when the patients is receiving timolol.

Ocular effects

Travoprost may gradually change the eye colour by increasing the number of melanosomes (pigment granules) in melanocytes. Before treatment is instituted patients must be informed of the possibility of these changes. Unilateral treatment can result in permanent heterochromia. The long term effects on the melanocytes and any consequences thereof are currently unknown. The change in iris colour occurs slowly and may not be noticeable for months to years. It may be permanent. The change in eye colour has predominantly been seen in patients with mixed coloured irides, i.e. blue-brown, grey-brown, yellow-brown and green-brown; however, it has also been observed in patients with brown eyes. Typically, the brown pigmentation around the pupil spreads concentrically towards the periphery in affected eyes, but the entire iris or parts of it may become more brownish. After discontinuation of therapy, no further increase in brown iris pigment has been observed.

Periorbital and/or eyelid skin darkening and deepening of the eyelid sulcus have been reported in association with the use of Travoprost.

Eyelash changes occurred in over a third of patients treated with DuoTrav Eye Drops. These changes include: increased length, thickness, pigmentation, and/or number of lashes.

There is no experience of DuoTrav Eye Drops in inflammatory ocular conditions, inflammatory, neovascular, angle-closure or congenital glaucoma and only limited experience in open-angle glaucoma of pseudophakic patients and in pigmentary glaucoma.

Although not reported during pivotal clinical trials with DuoTrav Eye Drops, macular oedema, including cystoid macular oedema, has been reported during treatment with prostaglandin F2α analogues. These reports have mainly occurred in aphakic patients, pseudophakic patients with a torn posterior lens capsule or anterior chamber lenses, or in patients with known risk factors for macular oedema. DuoTrav Eye Drops should be used with caution in these patients.

DuoTrav Eye Drops should be used with caution in patients with active intraocular inflammation, as well as patients with predisposing risk factors for uveitis.

Choroidal detachment has been reported with administration of aqueous suppressant therapy (e.g. timolol, acetazolamide) after filtration procedures.

Use of contact lens(es)

If patients continue to wear contact lenses while under treatment with DuoTrav Eye Drops they should remove their lens(es) prior to instilling DuoTrav Eye Drops in the affected eye(s) and should not insert their lens(es) until 15 minutes after instillation of the eye drops.

Actions the health care professional should take

Systemic absorption can be minimised if patients are instructed to gently occlude the nasolacrimal ducts for two minutes immediately after instillation of the eye drop.

Paediatric population

DuoTrav Eye Drops is not recommended for use in children. The safety and effectiveness in paediatric patients have not been established.
Use in the Elderly

No overall differences in safety and effectiveness have been reported between elderly and other adult patients.

Hepatic/Renal Impairment

No dosage alteration of DuoTrav Eye Drops is necessary in these patients.

4.5 Interactions with other medicinal products and other forms of interactions

No pharmacokinetic interactions were observed between travoprost and timolol following topical ocular administration of DuoTrav Eye Drops. No specific interaction studies were performed with DuoTrav Eye Drops and other drugs.

Travoprost

The plasma protein binding of the active free acid form of travoprost is moderate (approximately 80%) and, therefore, drug-drug interactions involving protein binding are unlikely.

Timolol

The potential exists for additive effects resulting in hypotension, and/or marked bradycardia when timolol ophthalmic drops are administered with oral calcium channel blockers, catecholamine depleting drugs or β-adrenergic blocking agents, antiarrhythmics (including amiodarone and quinidine), digitalis glycosides, parasympathomimetic, narcotics and monoamine oxidase inhibitors (MAOIs).

Potentiated systemic beta-blockade (e.g., decreased heart rate, depression) has been reported during combined treatment with CYP2D6 inhibitors (e.g. quinidine, fluoxetine, paroxetine) and timolol.

Beta blockers can decrease the response to adrenaline used to treat anaphylactic reactions.

Special caution should be exercised in patients with a history of atopy or anaphylaxis. (See Section 4.4. Special warnings and precautions for use).

Although DuoTrav Eye Drops used alone has little or no effect on pupil size, mydriasis has occasionally been reported when timolol is given with adrenaline.

Beta-blockers may increase the hypoglycaemic effect of antidiabetic agents.

4.6 Fertility, pregnancy and lactation

Pregnancy

Category C3

No adequate and well-controlled studies have been performed in pregnant women. DuoTrav Eye Drops may interfere with the maintenance of pregnancy. It should not be used by women during pregnancy or by women attempting to become pregnant.

Animal studies in travoprost and timolol are included in Section 5.3. Preclinical safety data.

Breast-feeding

Nursing women who use DuoTrav Eye Drops should use caution because of the potential for serious adverse reactions from DuoTrav Eye Drops in breastfeeding infants.

Because many drugs are excreted in human milk and adverse effects in rat pups were observed at low doses of travoprost nursing women who use DuoTrav Eye Drops
should stop breastfeeding.

Animal studies in travoprost and timolol are included in Section 5.3. Preclinical safety data.

Fertility

There are no human data on the effects of DuoTrav Eye Drops on male or female fertility.

Animal studies in travoprost and timolol are included in Section 5.3. Preclinical safety data.

4.7 Effects on ability to drive or use machines

As with other ophthalmic medications, patients should be advised to exercise caution if they experience transient blurred vision following instillation of eye drops. Patients should wait until their vision clears before driving or using machinery.

4.8 Undesirable effects

Adverse events arising from clinical trials of 6 week to 12 month duration involving DuoTrav (POLYQUAD-preserved) were consistent with the known safety profile for DuoTrav (BAK-preserved).

**DuoTrav (POLYQUAD-preserved)**

In 3 clinical trials involved in the development of DuoTrav (POLYQUAD-preserved), 372 patients/subjects were exposed for up to 12 months. The most frequently reported treatment-related undesirable effect with DuoTrav (POLYQUAD-preserved) was hyperaemia of the eye (11.8%), which included ocular or conjunctival hyperaemia. The majority of patients (91%) who experienced hyperaemia of the eye did not discontinue therapy as a result of this reaction.

The following adverse reactions listed below were observed in clinical studies or with post-marketing experience. They are ranked according to system organ class and classified according to the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1000 to <1/100), rare (≥1/10,000 to <1/1000), very rare (<1/10,000), or not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in decreasing order of seriousness.

The following adverse reactions listed below were observed in the clinical studies.

**Immune system disorders**

Uncommon: hypersensitivity.

**Nervous system disorders**

Uncommon: headache.

**Eye disorders**

Common: eye pain, ocular discomfort, dry eye, eye pruritus, ocular hyperaemia.

Uncommon: punctate keratitis, iritis, photophobia, vision blurred, conjunctivitis, meibomianitis, eyelid margin crusting, asthenopia, lacrimation increased, growth of eye lashes.

**Cardiac disorders**

Uncommon: bradycardia.

**Vascular disorders**
Uncommon: hypotension.

Skin and subcutaneous tissue disorders
Uncommon: skin discolouration, hair growth abnormal.

General disorders and administration site conditions
Uncommon: fatigue.

Investigations
Uncommon: heart rate decreased.

Additional adverse reactions that have been seen with one of the active substances and may potentially occur with DuoTrav.

Travoprost
Eye disorders
Uveitis, conjunctival disorder, conjunctival follicles, iris hyperpigmentation.

Skin and subcutaneous tissue disorders
Skin exfoliation.

Timolol
Metabolism and nutrition disorders
Hypoglycaemia.

Nervous system disorders
Cerebral ischaemia, myasthenia gravis.

Eye disorders
Diplopia.

Cardiac disorders
Cardiac arrest, atrioventricular block, palpitations.

Respiratory, thoracic and mediastinal disorders
Respiratory failure, nasal congestion.

Gastrointestinal disorders
Diarrhoea, nausea.

General disorders and administration site conditions
Asthenia.

Post Marketing Experience
The following adverse reactions have been reported during clinical studies with DuoTrav (POLYQUAD-preserved) and are classified according to the subsequent convention: very common (≥ 1/10), common (≥ 1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000) and very rare (<1/10,000). Within each frequency-grouping, adverse reactions are presented in order of decreasing seriousness.

Immune system disorders
Uncommon: hypersensitivity.
Nervous system disorders
Uncommon: headache.

Eye disorders
Common: eye pain, dry eye, eye pruritus, ocular discomfort, ocular hyperaemia.
Uncommon: punctate keratitis, iritis, conjunctivitis, vision blurred, photophobia, eyelids pruritus, asthenopia, meibominitis, eyelid margin crusting, growth of eyelashes.

Cardiac disorders
Uncommon: bradycardia.

Vascular disorders
Uncommon: hypotension.

Skin and subcutaneous tissue disorders
Uncommon: skin discolouration.

Additional adverse reactions identified from post-marketing surveillance include the following. Frequencies cannot be estimated from the available data.

Nervous system disorders
Dizziness.

Eye disorders
Macular oedema, keratitis, blepharitis, conjunctivitis, erythema of eyelid, eye swelling, lacrimation increased, eyelid oedema, eyelid ptosis, eye irritation.

Cardiac disorders
Chest pain, palpitations.

Vascular disorders
Hypertension.

Respiratory, thoracic and mediastinal disorders
Dyspnoea, cough, asthma.

Skin and subcutaneous tissue disorders
Alopecia.

DuoTrav (BAK-preserved)
In clinical studies involving 938 patients, DuoTrav (BAK-preserved) was administered once-daily. No serious ophthalmic or systemic adverse reactions related to DuoTrav were reported. The most frequently reported treatment-related adverse reaction was ocular hyperaemia (15.0%). Almost all patients (96%) who experienced ocular hyperaemia did not discontinue therapy as a result of this reaction.

The following adverse reactions listed below were observed in clinical studies or with post-marketing experience. They are ranked according to system organ class and classified according to the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1000 to <1/100), rare (≥1/10,000 to <1/1000), very rare (<1/10,000), or not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in decreasing order of seriousness.

Psychiatric disorders

Internal Document code
Duo180118iNZ
Common: nervousness.
Not known: depression.

Nervous system disorders
Common: dizziness, headache.
Not known: cerebrovascular accident, syncope, paraesthesia.

Eye disorders
Very common: ocular discomfort, ocular hyperaemia.
Common: punctate keratitis, anterior chamber inflammation, eye pain, photophobia, eye swelling, conjunctival haemorrhage, visual acuity reduced, visual disturbance, vision blurred, dry eye, eye pruritus, conjunctivitis, lacrimation increased, erythema of eyelid, blepharitis, asthenopia, growth of eyelashes.
Uncommon: corneal erosion, keratitis, eye allergy, conjunctival oedema, eyelid oedema.
Rare: iritis.
Not known: macular oedema, eyelid ptosis, corneal disorder.

Cardiac disorders
Common: heart rate irregular, heart rate decreased.
Uncommon: arrhythmia.
Not known: cardiac failure, tachycardia.

Vascular disorders
Common: blood pressure increased, blood pressure decreased.

Respiratory, thoracic and mediastinal disorders
Common: bronchospasm.
Uncommon: dyspnoea, cough, oropharyngeal pain, throat irritation, nasal discomfort, postnasal drip.
Not known: asthma.

Hepatobiliary disorders
Uncommon: alanine aminotransferase increased, aspartate aminotransferase increased.

Skin and subcutaneous tissue disorders
Common: urticaria, skin hyperpigmentation (periocular).
Uncommon: dermatitis contact.
Rare: alopecia.
Not known: rash.

Musculoskeletal and connective tissue disorders
Common: pain in extremity.

Renal and urinary disorders
Uncommon: chromaturia.

General disorders and administration site conditions
Uncommon: thirst.

Not known: chest pain.

**Post Marketing Experience**

The following adverse reactions have been reported during clinical studies with DuoTrav (BAK-preserved) and are classified according to the subsequent convention: very common (≥ 1/10), common (≥ 1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000) and very rare (<1/10,000). Within each frequency-grouping, adverse reactions are presented in order of decreasing seriousness.

**Immune system disorders**

Uncommon: hypersensitivity.

**Nervous system disorders**

Uncommon: dizziness, headache.

**Eye disorders**

Very common: ocular hyperaemia.

Common: punctate keratitis, vision blurred, dry eye, eye pain, eye pruritus, ocular discomfort, eye irritation.

Uncommon: keratitis, iritis, conjunctivitis, anterior chamber inflammation, blepharitis, photophobia, visual acuity reduced, asthenopia, conjunctival haemorrhage, eye swelling, lacrimation increased, erythema of eyelid, growth of eyelashes

Rare: corneal erosion, trichiasis, distichiasis.

**Cardiac disorders**

Uncommon: bradycardia.

**Vascular disorders**

Uncommon: hypertension, hypotension.

**Respiratory, thoracic and mediastinal disorders**

Uncommon: dyspnoea, bronchospasm, cough

Rare: dysphonia, throat irritation.

**Skin and subcutaneous tissue disorders**

Uncommon: dermatitis contact, hypertrichosis, skin hyperpigmentation.

Rare: urticaria.

Additional adverse reactions identified from post-marketing surveillance include the following. Frequencies cannot be estimated from the available data.

**Psychiatric disorder**

Depression.

**Eye disorders**

Macular oedema.

**Cardiac disorders**

Chest pain, palpitations.
Vascular disorders
Oedema peripheral.

Respiratory, thoracic and mediastinal disorders
Asthma.

Skin and subcutaneous tissue disorders
Alopecia.

Gastrointestinal disorders
Dysgeusia.

**Tabulated summary of adverse drug reactions from clinical trials**
The following adverse reactions have been reported during clinical studies with Duotray Eye Drops and are classified according to the subsequent convention: very common (≥ 1/10), common (≥ 1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/10,000) and very rare (<1/10,000).

<table>
<thead>
<tr>
<th>System organ classification</th>
<th>Adverse reactions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immune system disorders</td>
<td>Uncommon: hypersensitivity.</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>Uncommon: dizziness, headache.</td>
</tr>
<tr>
<td>Cardiac disorders</td>
<td>Uncommon: bradycardia.</td>
</tr>
<tr>
<td>Vascular disorders</td>
<td>Uncommon: hypertension, hypotension.</td>
</tr>
<tr>
<td>Respiratory, thoracic and mediastinal disorders</td>
<td>Uncommon: dyspnea. Rare: dysphonia, bronchospasm, cough, throat irritation.</td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td>Uncommon: dermatitis contact, hypertrichosis, skin hyperpigmentation (periorbital or eyelid pigmentation). Rare: urticaria, skin discolouration.</td>
</tr>
</tbody>
</table>
Adverse drug reactions from spontaneous reports and literature cases (frequency not known)
The following adverse drug reactions have been derived from post-marketing experience with DuoTrav Eye Drops via spontaneous case reports and literature cases. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency which is therefore categorized as not known. Adverse drug reactions are listed according to system organ classes in MedDRA.

<table>
<thead>
<tr>
<th>System organ classification</th>
<th>Adverse reactions MedDRA Preferred Term (v.19.1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Psychiatric disorders</td>
<td>Depression.</td>
</tr>
<tr>
<td>Eye disorders</td>
<td>Macular oedema, eyelid ptosis, lid sulcus deepened, iris hyperpigmentation.</td>
</tr>
<tr>
<td>Cardiac disorders</td>
<td>Chest pain, palpitations.</td>
</tr>
<tr>
<td>Vascular disorders</td>
<td>Oedema peripheral.</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>Dysgeusia.</td>
</tr>
<tr>
<td>Respiratory, thoracic and mediastinal disorders</td>
<td>Asthma.</td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td>Rash, alopecia.</td>
</tr>
</tbody>
</table>

Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions https://nzphvc.otago.ac.nz/reporting.

4.9 Overdose
There are no human data available on overdosage with DuoTrav Eye Drops, although overdosage data are available on timolol, one of its individual active constituents.

If DuoTrav Eye Drops is accidentally ingested the following information should be useful. One 2.5 mL bottle contains travoprost 0.1 mg and timolol 12.5 mg. Both timolol and travoprost are extensively metabolised in the liver.

Travoprost
A single-dose intravenous study in rats was conducted to elucidate maximal acute hazard. The dose employed was 250,000 times the proposed daily clinical exposure and over 5,000 times the possible exposure from the entire contents of one product container. No treatment related pharmacotoxic signs were present in the animals receiving travoprost.

Timolol
Symptoms of systemic timolol overdosage are bradycardia, hypotension, bronchospasm and cardiac arrest. If such symptoms occur, treatment should be symptomatic and supportive. Studies have shown that timolol is not readily dialysable.

If overdosage with DuoTrav Eye Drops occurs, treatment should be symptomatic.
A topical overdose of DuoTrav Eye Drops may be flushed from the eyes with warm tap water.

For advice on the management of overdose please contact the National Poisons Centre on 0800 POISON or 0800 764 766.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic Group: ophthalmologicals; anti-glaucoma preparations and miotics-beta blocking agents-timolol, combinations. ATC Code S01ED51.

Mechanism of action

DuoTrav Eye Drops contains two active components, travoprost and timolol, which lower intraocular pressure (IOP) by complementary mechanisms of action.

Following the administration of DuoTrav Eye Drops, the reduction in IOP starts within 30 minutes and the maximum effect is reached after 12 hours. Significant IOP reduction is maintained for at least 24 hours after multiple treatments.

Glaucoma is defined as an optic neuropathy resulting in optic nerve head damage and visual field loss. The pathogenesis of glaucoma is multi-factorial; the primary risk factors, however, are considered to be sustained elevated IOP and poor ocular perfusion.

Pharmacodynamic effects

Clinical studies have shown that DuoTrav Eye Drops results in additional IOP reduction compared to either component administered alone and that the IOP-lowering effect is comparable to Travatan Eye Drops (travoprost 0.004%) and timolol 0.5% administered concomitantly once daily.

**Travoprost:** Travoprost is an ester prodrug of a PGF$_{2\alpha}$ analogue and is hydrolysed to the active acid. The free acid is a prostaglandin FP receptor agonist. PGF$_{2\alpha}$ analogues are believed to reduce the intraocular pressure (IOP) by increasing the outflow of aqueous humour via trabecular meshwork and uveoscleral pathways. Reduction of IOP in man starts about 2 hours after administration and maximum effect is reached after twelve hours. Pressure reduction is maintained for at least twenty-four hours. Pivotal clinical studies have demonstrated that Travatan Eye Drops is effective as monotherapy at reducing IOP. Repeated observations over a period of one year indicate that the IOP-lowering effect of travoprost is well maintained. In addition, travoprost slightly, but significantly, increased optic nerve head blood flow in a single study in rabbits.

**Timolol:** Timolol maleate is a non-selective β1- and β2-adrenergic receptor blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anaesthetic (membrane stabilising) activity. Timolol lowers IOP by decreasing the formation of aqueous humour in the ciliary epithelium. The precise mechanism of action is not clearly established.

Clinical efficacy and safety

Clinical Studies with DuoTrav Eye Drops (POLYQUAD preserved, BAK free)

**Pharmacokinetics**

A double blind, two way crossover pharmacokinetic study (n=24) was conducted comparing DuoTrav Eye Drops preserved with POLYQUAD (BAK-free) or preserved with benzalkonium chloride (BAK). Patients were dosed in the morning for 5 days to evaluate the steady state plasma pharmacokinetics of travoprost (travoprost free acid (AL-
and timolol. Plasma concentrations were below the limit of quantitation (LOQ = 0.0100 µg/mL) in 94% of samples. $T_{\text{max}}$ and $T_{1/2}$ were similar for timolol.

**Efficacy Studies**

A randomised double blind clinical equivalence study (n=388) was conducted to compare DuoTrav (BAK-free) against DuoTrav (BAK). Patients with open angle glaucoma or ocular hypertension were dosed once daily in the morning for 6 weeks. The primary efficacy parameter was mean IOP at the 9 AM, 11 AM and 4 PM time points at Week 6. The percentage of patients with IOP < 18 mmHg or IOP percent reduction of ≥ 30% was a secondary variable.

DuoTrav Eye Drops (BAK-free) and DuoTrav Eye Drops (BAK) produced statistically equivalent IOP lowering efficacy. Mean IOP reductions from baseline for both formulations were clinically relevant and statistically significant at all measurement times. Mean IOP reductions ranged from 7.5 to 8.3 mmHg for DuoTrav Eye Drops (BAK-free) and from 8.1 to 8.5 mmHg for DuoTrav Eye Drops (BAK). Differences in mean IOP between DuoTrav Eye Drops (BAK-free) and DuoTrav Eye Drops (BAK) ranged from 0.1 to 0.7 mmHg when evaluated across all on therapy visits and times (i.e. 3 diurnal times at 2 visits).

The percentage of patients with IOP <18 mmHg or percent reduction ≥30% at each study visit ranged from 60% to 73% in the DuoTrav Eye Drops (BAK-free) group and from 67% to 73% in the DuoTrav Eye Drops (BAK) group. The estimates of pooled IOP response in the two treatment groups were similar and not statistically significantly different (67% vs 70%, p=0.3710). No clinically relevant safety differences were identified.

**Clinical Studies with DuoTrav Eye Drops (BAK)**

Adult patients with diagnoses of predominately primary open angle glaucoma, ocular hypertension or pigmentary glaucoma participated in three randomised, double-masked, parallel group multicentre studies (n=982) to demonstrate the safety and efficacy of DuoTrav Eye Drops. These studies evaluated the IOP-lowering effect of DuoTrav Eye Drops dosed once daily (morning) over three-months compared to:

- monotherapy with its individual components (mean baseline intraocular pressures of 27 to 30 mmHg), travoprost 0.004% dosed once daily (evening) and timolol 0.5% dosed twice daily (contribution-of-elements; Study 1)

- concomitant administration of travoprost 0.004% and timolol 0.5% (mean baseline intraocular pressures of 23 to 26 mmHg), both dosed once daily (evening and morning, respectively; Study 2). One study also used timolol 0.5% dosed twice daily (Study 3).

The primary efficacy parameter for all studies was mean IOP at 8 AM, 10 AM and 4 PM. The proportion of patients with IOP < 18 mmHg was measured as a secondary efficacy parameter.

Approximately 22% to 37% of the patients included in the studies were treatment-naïve patients. All other patients were receiving monotherapy (49% to 57%) with either timolol, a prostaglandin or other medication; two medications (11% to 17%) or three plus medications (2% to 4%).
In the contribution-of-elements study (Study 1), the mean IOP-lowering effect of DuoTrav Eye Drops dosed once-daily in the morning was 8.7 to 11.5 mmHg, and was 0.4 to 1.8 mmHg greater than Travatan 0.004% dosed once daily in the evening and 1.5 to 2.7 mmHg greater than that of timolol 0.5% dosed twice-daily. However there are no data to show the optimal dose of these agents in combination. In the two concomitant administration studies, the mean IOP reductions of DuoTrav Eye Drops were similar to those achieved by concomitant therapy with Travatan dosed once daily in the evening and timolol dosed once daily in the morning (see Table 1). Differences in mean IOP change from baseline at 10 AM and 4 PM were approximately 1 mmHg, favouring concomitant therapy. No differences were observed at 8 AM. When DuoTrav Eye Drops was compared to concomitant therapy (Study 2 and Study 3), non-inferiority was not demonstrated at all time points. However pooled analyses revealed non-inferiority. Six month extension data were consistent with previous findings in the individual studies.

DuoTrav Eye Drops yielded IOP < 18 mmHg at one or more time-points at all visits throughout the entire 3-month period for 50% of patients in the contribution-of-elements study, and for 74% of patients in a pooled analysis of the concomitant administration studies.

<table>
<thead>
<tr>
<th>Visit</th>
<th>Time point</th>
<th>Mean IOP (mmHg)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Study 2</td>
</tr>
<tr>
<td></td>
<td>DuoTrav</td>
<td>TRAVATAN</td>
</tr>
<tr>
<td></td>
<td>Eye Drops</td>
<td>Eye Drops +</td>
</tr>
<tr>
<td></td>
<td>(n=151)</td>
<td>Timolol qd</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(n=142)</td>
</tr>
<tr>
<td>Baseline</td>
<td>8AM</td>
<td>25.2</td>
</tr>
<tr>
<td></td>
<td>10AM</td>
<td>24.0</td>
</tr>
<tr>
<td></td>
<td>4PM</td>
<td>23.0</td>
</tr>
<tr>
<td>Week 2</td>
<td>8AM</td>
<td>16.2</td>
</tr>
<tr>
<td></td>
<td>10AM</td>
<td>15.5</td>
</tr>
<tr>
<td></td>
<td>4PM</td>
<td>15.2</td>
</tr>
<tr>
<td>Week 6</td>
<td>8AM</td>
<td>15.9</td>
</tr>
<tr>
<td></td>
<td>10AM</td>
<td>15.8</td>
</tr>
<tr>
<td></td>
<td>4PM</td>
<td>15.6</td>
</tr>
<tr>
<td>Month 3</td>
<td>8AM</td>
<td>16.6</td>
</tr>
<tr>
<td></td>
<td>10AM</td>
<td>16.1</td>
</tr>
<tr>
<td></td>
<td>4PM</td>
<td>15.6</td>
</tr>
</tbody>
</table>

Double-masked extensions of the three studies mentioned above were conducted for up to an additional three months. The IOP-lowering effect of DuoTrav Eye Drops was maintained during this period.

A separate dosing study (morning or evening) confirmed that the IOP-lowering efficacy of once-daily DuoTrav Eye Drops is independent of the time of dosing.
A similar safety profile was observed comparing therapy with DuoTrav Eye Drops to concomitant therapy with the individual components (travoprost 0.004% + timolol 0.5%) or to monotherapy with each component (travoprost 0.004%; timolol 0.5%).

5.2 Pharmacokinetic properties

Absorption
Travoprost and timolol are absorbed through the cornea. Travoprost undergoes rapid ester hydrolysis in the cornea to the active free acid. Following topical ocular administration of DuoTrav Eye Drops (POLYQUAD preserved) once-daily in healthy subjects (n=22) for 5 days, the travoprost free acid was not quantifiable in plasma samples from the majority of subjects (94.4%) and generally was not detectable in samples one hour after dosing. In those subjects in whom travoprost free acid was measurable (≥0.01 ng/mL, the assay limit of quantitation), plasma concentration ranged from 0.01 to 0.03 ng/mL. The mean peak timolol steady-state concentration was 1.34 ng/mL after once-daily administration of DuoTrav Eye Drops (POLYQUAD preserved). Timolol T<sub>max</sub> was approximately 0.69 hours after dosing.

Distribution
Travoprost free acid can be measured in the aqueous humour during the first few hours in animals and in human plasma only during the first hour after topical ocular administration of DuoTrav Eye Drops. Timolol can be measured in human aqueous humour after topical ocular administration of timolol and in plasma for up to 12 hours after topical ocular administration of DuoTrav Eye Drops.

Biotransformation
The metabolic pathways of the travoprost free acid parallel those of endogenous PGF<sub>2α</sub> and are characterised by reduction of the 13-14 double bond, oxidation of the 15-hydroxyl group and β-oxidation of the carboxylic acid chain. The plasma elimination of the free acid was rapid with a mean apparent t<sub>1/2</sub> of approximately 45 minutes. There was no difference in plasma concentrations between Days 1 and 3, indicating lack of drug accumulation following repeated administration of DuoTrav Eye Drops. Timolol is extensively metabolised in the liver. The apparent terminal elimination t<sub>1/2</sub> of timolol in plasma was approximately 4 hours after topical ocular administration of DuoTrav Eye Drops.

Elimination
Travoprost free acid and its metabolites are mainly excreted by the kidneys. In humans, less than 2% of a topical ocular dose of travoprost was recovered in urine as free acid. Timolol and its metabolites are primarily excreted by the kidneys. Approximately 20% of a timolol dose is excreted in the urine unchanged and the remainder excreted in urine as metabolites.

5.3 Preclinical safety data

Pregnancy
Travoprost. The human dose of travoprost with the recommended dosage of DuoTrav Eye Drops is 2.2 µg/day or 0.044 µg/kg/day, with plasma concentrations of up to 0.020 ng/mL. Travoprost and/or its metabolites crossed the placenta in rats. Travoprost was teratogenic in rats at intravenous doses of 10 µg/kg/day, equivalent to 98 times the human exposure; it increased the incidence of hydrocephaly and bone abnormalities (e.g. vertebral malformations). Travoprost was not teratogenic in rats at intravenous doses of up to 3 µg/kg/day (29 times the human exposure). When administered to rats during
organogenesis (gestation days 6 to 17), travoprost produced increases in post-implantation loss and early delivery at intravenous doses of 10 \( \mu g/kg/day \) (98 times the human exposure). Post-implantation loss increased in rats at subcutaneous doses of 10 \( \mu g/kg/day \) (54 times human exposure) administered from 2 weeks prior to mating to gestation day 7. Travoprost was not teratogenic in mice at subcutaneous doses of up to 0.3 \( \mu g/kg/day \); post-implantation loss and early delivery were increased in mice at subcutaneous doses of 1 \( \mu g/kg/day \) (5.8 times the human exposure), but not at 0.3 \( \mu g/kg/day \) (1.7 times the human exposure).

Travoprost Eye Drops, 0.003% administered to rabbits during organogenesis, appeared to increase incidence of fetal loss.

In rats administered travoprost from gestation day 7 to lactation day 21 by subcutaneous injection, abortions occurred at 0.72 \( \mu g/kg/day \) (4 times human exposure), and decreased gestation length and increased still births occurred at \( \geq 0.12 \mu g/kg/day \) (0.65 times human exposure). See also Breast-feeding below.

**Timolol**: Timolol maleate was not teratogenic in mice, rats and rabbits. Embryofetal development studies with timolol maleate in mice and rabbits showed no evidence of embryofetal toxicity at doses up to 50 mg/kg/day. At higher doses, increases in resorptions and fetal variations (14 ribs and hypoplastic sternebrae) were noted in mice (1,000 mg/kg/day) and increased resorption in rabbits (\( \geq 90 \) mg/kg/day). In rats, delayed ossification was seen at \( \geq 50 \) mg/kg/day and a decreased number of caudal vertebral bodies and arches and an increase in hypoplastic sternebrae were noted at 500 mg/kg/day.

Epidemiological studies show a risk for intra-uterine growth retardation when beta-blockers are administered by the oral route. In addition, signs and symptoms of beta-blockade (e.g. bradycardia, hypotension, respiratory distress and hypoglycaemia) have been observed in the neonate when systemic beta-blockers have been administered to the mother until delivery.

**Breast-feeding**

**Travoprost**: There are no data on the excretion of travoprost into human milk or on the safety of travoprost exposure in infants. A study in rats showed that travoprost and/or its metabolites were excreted in milk. Increased pup mortality and depressed pup growth and development occurred in rats where the dams were subcutaneously administered travoprost from gestation day 7 to lactation day 21 at greater than or equal to 0.12 \( \mu g/kg/day \), corresponding to 2.7 the expected human dose.

**Timolol**: Timolol maleate has been detected in human milk following oral and ocular administration.

**Fertility**

**Travoprost**: Travoprost had no effects on mating behaviour or fertility in male and female rats at subcutaneous doses up to 10 \( \mu g/kg/day \) (equivalent to 54 times the human exposure at the MRHOD), although embryofetal resorption was increased at 10 \( \mu g/kg/day \) (further information on effects on pregnancy is included in Pregnancy above).

**Timolol**: Timolol maleate alone had no effects on male or female fertility when administered at 300 \( \mu g/kg/day \), PO.

**Carcinogenic potential**

Carcinogenicity studies with DuoTrav Eye Drops have not been conducted.
Travoprost: Long term studies in mice and rats at subcutaneous doses up to 100 µg/kg/day did not provide any evidence of carcinogenic potential. These doses correspond to exposure levels over 200 times human exposure at the maximum recommended human ophthalmic dose (MRHOD), based on plasma active drug levels.

Timolol: No evidence of carcinogenicity was observed with timolol maleate at oral doses up to 100 mg/kg/day in rats and 50 mg/kg/day in mice. However, there was a statistically significant increase in the incidence of adrenal phaeochromocytomas in male rats administered 300 mg/kg/day. In female mice, statistically significant increases in the incidence of benign and malignant pulmonary tumours, benign uterine polyps and mammary carcinomas were found at 500 mg/kg/day. The increased incidence of mammary tumours was considered to be attributed to a species elevation in serum prolactin.

Genotoxicity

Mutagenicity studies with DuoTrav Eye Drops have not been conducted.

Travoprost: Travoprost did not cause gene mutation in bacteria or chromosomal aberrations in bone marrow cells of mice and rats. A slight increase in mutation frequency was observed in one of two mouse lymphoma L5178Y assays. Weight of evidence indicates that travoprost is unlikely to pose a genotoxic risk from clinical use.

Timolol: In vitro and in vivo studies with timolol maleate did not reveal a mutagenic potential.

6. PHARMACEUTICAL PARTICULARS

6.1. List of excipients
Polyquaternium-1 (POLYQUAD™)
Castor oil – ethoxylated hydrogenated
Propylene glycol
Boric acid
Mannitol
Sodium chloride
Sodium hydroxide and/or hydrochloric acid (for pH adjustment)
Purified water.

6.2 Incompatibilities
Not known.

6.3 Shelf life
24 months.

6.4 Special precautions for storage
Store below 25°C.
Discard container 4 weeks after opening.

6.5 Nature and contents of container
2.5 mL oval DROP-TAINER™ bottle with our without a pouch dispenser.

6.6 Special precautions for disposal
No special requirements for disposal.

7. MEDICINE SCHEDULE
Prescription Only Medicine.

8. **SPONSOR**

Novartis New Zealand Limited
109 Carlton Gore Road
Newmarket
Auckland 1023.
PO Box 99102
Newmarket
Auckland 1149
New Zealand.
Free Phone: 0800 354 335.

9. **DATE OF FIRST APPROVAL**

26 May 2011.

10. **DATE OF REVISION OF THE TEXT**

16 January 2018.

Summary Table of Changes

<table>
<thead>
<tr>
<th>Data Sheet – all sections.</th>
<th>Updated to Summary of Product Characteristics format.</th>
</tr>
</thead>
<tbody>
<tr>
<td>8. Sponsor.</td>
<td>Change in sponsor from Pharmaco to Novartis.</td>
</tr>
</tbody>
</table>

TM Trademark of Novartis.